DAVID KERSHENOBICH, M.D., PH.D.; MlSAEL URIBE, M.D.; GLORIA IRENE SUÁREZ, M.B.; RUY PÉREZ TAMAYO, M.D.; MARCOS ROJKIND, M.D., PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Although colchicine has been used in humans for several centuries as an anti-inflammatory agent in acute gout, its pharmacologic properties as well as its metabolism and toxicity are not yet completely know.
Two recent reports, one by Dr. Ravid and colleagues (1) in which colchicine given to patients with amyloidosis produced gradual remission of the nephrotic syndrome and a rise of serum albumin to normal levels, and another by Wilfred (2) in which colchicine administered in vivo to rats increased hepatic alkaline phosphatase activity, are interesting and provocative observations.
We are conducting a double-blind trial designed to
KERSHENOBICH D, URIBE M, SUÁREZ GI, TAMAYO RP, ROJKIND M. Colchicine, Serum Albumin, and Alkaline Phosphatase. Ann Intern Med. ;89:144. doi: 10.7326/0003-4819-89-1-144_1
Download citation file:
Published: Ann Intern Med. 1978;89(1):144.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use